NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor MM

NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) from developing multiple myeloma.

The names of the study drug involved in this study is:

Metformin, extended release

Placebo (a pill that has no active ingredients)

Sponsor:

Dana-Farber Cancer Institute

Collaborator:

National Cancer Institute (NCI)

---

ClinicalTrials.gov Identifier: NCT04850846

Official Title: A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

First Posted: April 20, 2021

Click here to see details on ClinicalTrials.gov

---

Drug: Metformin XR

Other: Placebo

---

Locations

United States, Massachusetts

United States, New Hampshire